Edition:
United States

Glenmark Pharmaceuticals Ltd (GLEN.NS)

GLEN.NS on National Stock Exchange of India

611.85INR
5:11am EDT
Change (% chg)

Rs-3.30 (-0.54%)
Prev Close
Rs615.15
Open
Rs617.60
Day's High
Rs620.00
Day's Low
Rs610.25
Volume
515,639
Avg. Vol
1,424,725
52-wk High
Rs994.00
52-wk Low
Rs567.80

Latest Key Developments (Source: Significant Developments)

Glenmark Pharma gets ANDA approval for nitroglycerin sublingual tablets
Tuesday, 19 Sep 2017 11:18pm EDT 

Sept 20 (Reuters) - Glenmark Pharmaceuticals Ltd :Says receives ANDA approval for nitroglycerin sublingual tablets usp, 0.3 mg, 0.4 mg, and 0.6 mg.  Full Article

Glenmark Pharmaceuticals gets ANDA approval for desonide ointment, 0.05 pct
Monday, 18 Sep 2017 11:22pm EDT 

Sept 19 (Reuters) - Glenmark Pharmaceuticals Ltd :Says Glenmark Pharmaceuticals receives ANDA approval for desonide ointment, 0.05%.  Full Article

Glenmark Pharmaceuticals gets ANDA approval for acyclovir ointment USP, 5 pct
Tuesday, 1 Aug 2017 11:35pm EDT 

Aug 2 (Reuters) - Glenmark Pharmaceuticals Ltd :Says Glenmark Pharmaceuticals receives ANDA approval for acyclovir ointment USP, 5%.  Full Article

Glenmark Pharmaceuticals reports positive data in phase 2A study of GBR 830 for treatment of patients with atopic dermatitis
Monday, 31 Jul 2017 11:41am EDT 

July 31 (Reuters) - Glenmark Pharmaceuticals Ltd ::Glenmark Pharmaceuticals reports positive data in a phase 2A study of GBR 830 for the treatment of patients with atopic dermatitis.‍Firmly committed to advancing GBR 830 for patients with AD, plans to initiate a Phase 2B trial in H1 of calendar year 2018​.  Full Article

India's Glenmark Pharmaceuticals June qtr consol profit up about 47 pct
Thursday, 27 Jul 2017 06:48am EDT 

July 27 (Reuters) - Glenmark Pharmaceuticals Ltd :June quarter consol profit 3.33 billion rupees versus profit of 2.27 billion rupees last year.Consensus forecast for june quarter consol profit was 2.93 billion rupees.June quarter consol revenue from operations 23.63 billion rupees versus 19.69 billion rupees last year.Says "despite challenges in India and US markets, the performance of these businesses have been good".  Full Article

Glenmark pharmaceuticals enters exclusive agreement with Cyndea Pharma S.L.
Tuesday, 18 Jul 2017 10:00am EDT 

July 18 (Reuters) - Glenmark Pharmaceuticals Ltd ::Entered into a development, license, manufacture and commercial supply agreement with Cyndea Pharma S.L..Under agreement, co receives exclusive rights to United States, Canada markets for generic,soft-gelatin capsule formulations.Under agreement, co receives exclusive rights in exchange for sharing development costs and profits from future sales.  Full Article

Glenmark Pharmaceuticals gets ANDA approval for hypertension treating tablets
Thursday, 6 Jul 2017 11:14pm EDT 

July 7 (Reuters) - Glenmark Pharmaceuticals Ltd :Says Glenmark Pharmaceuticals receives ANDA approval for amlodipine and olmesartan medoxomil tablets.  Full Article

Glenmark Pharma gets MHRA approval for anti-malarial medication as pharmacy license in UK
Monday, 3 Jul 2017 11:14pm EDT 

July 4 (Reuters) - Glenmark Pharmaceuticals Ltd :Says receives MHRA, UK approval for Maloff protect, anti-malarial medication as a pharmacy license in UK.  Full Article

Glenmark Pharmaceuticals gets ANDA approval for indomethacin extended-release capsules USP, 75 mg
Monday, 26 Jun 2017 11:20pm EDT 

June 27 (Reuters) - Glenmark Pharmaceuticals Ltd :Says Glenmark Pharmaceuticals receives ANDA approval for indomethacin extended-release capsules USP, 75 mg.  Full Article

Glenmark Pharmaceuticals gets tentative ANDA approval for drug to treat overactive bladder
Wednesday, 21 Jun 2017 11:19pm EDT 

June 22 (Reuters) - Glenmark Pharmaceuticals Ltd :Receives tentative ANDA approval for Solifenacin Succinate tablets, 5 mg and 10 mg.  Full Article

BRIEF-Glenmark Pharma gets ANDA approval for nitroglycerin sublingual tablets

* Says receives ANDA approval for nitroglycerin sublingual tablets usp, 0.3 mg, 0.4 mg, and 0.6 mg Source text for Eikon: Further company coverage: